Subsequent trials showed the treatment of ETC inhibitors, pyruvate dehydrogenase inhibitors, or mitochondrial ClpP protease agonists largely postponed the relapse following VEN + Ara-c treatment, promoting new potential therapeutic targets related to metabolism in AML [134]. This evidence concerns the gene CLPP and acute myeloid leukemia.